ChemBriefMajor Novartis Shareholder Calls for Board Shake-Up After Drug Trial Setbacks
Artisan Partners urges Novartis board changes after failed drug trials wiped nearly $30 billion from its market value. The shareholder criticizes the company's M&A strategy and compensation structure,
reuters · 2026-09-10 03:22